News

Digital Therapeutics is game changer in chronic disease mgmt: Phable study

The study showcases conclusive results for Type 2 Diabetes and Hypertension 

Phable unveiled insights from their recent clinical studies conducted for Hypertension and Type 2 Diabetes. The studies were presented at the BPCON Conference 2022 – Annual Meeting of Indian Society of Hypertension, Lucknow and at the RSSDI Conference 2022 – Annual Meeting of Research Society of the Study of Diabetes in India, Chennai. 

THIS CAN BE YOUR ADVERTISEMENT

The studies established that digital therapeutics (DTx) intervention, applied through Phable’s proprietary algorithm and smartphone devices, helped chronic disease patients regain control of their health. 

Chronic diseases such as Type 2 Diabetes and Hypertension are called lifestyle diseases because their risk factors are linked to one’s way of living. The management of these conditions requires regular self-monitoring and behaviour change, which seem like the easiest things to do but are difficult to stick to. Health-related behaviour change needs consistency and constant nudging to become an implementable reality. 

Technology-driven behaviour changes powered by Phable’s algorithm and applied through a smartphone can be the constant companion that chronic disease patients need. Using smartphones, wearables, and monitoring devices, patients can self-monitor their health parameters and report them to the Phable app. Phable’s proprietary algorithm takes in the health signals and suggests suitable actions to help drive behaviour change and treatment adherence in patients. Chronic disease patients can take control of their health with Phable, which is supported by the expertise of 17,000 doctors and the experience of helping 4.5 million Indians on their health journey.   

The advantages of adopting smartphone-enabled monitoring of chronic diseases are numerous and varied. Therefore, it needs to be adopted quickly by patients and doctors alike. Phable’s recent studies go on to establish the effectiveness of DTx in chronic disease management. 

The study on the role of Digital Therapeutics in the management of Type 2 Diabetes was conducted over 12 weeks in Type 2 Diabetes patients. The DTx intervention included a specifically designed interactive and algorithmic management of diet, physical movement, health education, and self-monitoring via the Phable App. 

The study found that patients with Type 2 Diabetes benefited significantly from Phable’s proprietary Diabetes Management programme, as seen by a reduction of their HbA1c values (an average of blood glucose levels in the past 3 months) at the end of the 12 weeks. Particularly, patients with higher severity of Diabetes saw a significantly greater improvement in blood sugar control. It was also found that patients who had been diagnosed with Type 2 Diabetes within the last 1 year saw much greater benefits from the digital therapeutic intervention. 

As per the results, after 12 weeks, patients with HbA1c levels ≥ 8 per cent showed a change in HbA1c of -1.45 per cent. Also, patients with Diabetes of less than 1-year duration showed a change in HbA1c of -1.96 per cent.  

These results show that compared to conventional healthcare models, Phable’s DTx-enabled intervention has proved to be more effective in improving blood sugar control through behaviour change and self-management of diabetes in patients.  

The study on blood pressure control was conducted over 12 weeks on patients with uncontrolled hypertension (BP ≥140/90 mmHg) under stable treatment. The interventions under DTx included proprietary algorithmic management of hypertension through – dietary modification, stress management, physical activity, patient education, and self-monitoring.  

The results showed that the mean blood pressure of the patients reduced by 28/19 mmHg from a baseline reading of 155/100 mmHg to 127/82 mmHg. Amongst the patients, 82.4 per cent achieved the European Society of Cardiology (ESC) and Indian Council of Medical Research (ICMR) recommended goal of systolic blood pressure <140 mmHg. Also, 67.6 per cent of patients returned to controlled blood pressure levels of <140/90 mmHg and 35.2 per cent achieved the optimum blood pressure reading of <130/80 mmHg. Notably, as the severity of hypertension increased, the benefit in terms of reduction in blood pressure also increased. 

These results establish the effectiveness of Phable’s DTx intervention in improving the blood pressure values of patients through behaviour modification and self-management of hypertension. 

Speaking on the results from the clinical studies, Dr Suhas Patil, Health Strategy Lead, Phable, stated, “The studies were conducted to irrefutably demonstrate that a smartphone – an everyday device, can help monitor as well as manage chronic diseases, through precision in therapy and personalization of treatment. DTx, which makes use of mobile applications and analytics, can help achieve the remission of chronic diseases. A sustained DTx intervention, over time, will help patients lower their dependency on medicines. These studies bring out the importance and urgency of DTx adoption to lead healthier lives.” 

 

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
Close
Close